Form 8-K - Current report:
SEC Accession No. 0001104659-20-089747
Filing Date
2020-08-04
Accepted
2020-08-03 19:08:41
Documents
6
Period of Report
2020-07-31
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 3.02: Unregistered Sales of Equity Securities
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K tm2026370d1_8k.htm 8-K 28231
2 EXHIBIT 4.1 tm2026370d1_ex4-1.htm EX-4.1 104840
3 EXHIBIT 10.1 tm2026370d1_ex10-1.htm EX-10.1 241581
4 EXHIBIT 10.2 tm2026370d1_ex10-2.htm EX-10.2 133344
5 EXHIBIT 99.1 tm2026370d1_ex99-1.htm EX-99.1 9929
6 GRAPHIC image_001.jpg GRAPHIC 3117
  Complete submission text file 0001104659-20-089747.txt   523877
Mailing Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036
Business Address 7 TIMES SQUARE SUITE 2503 NEW YORK NY 10036 6462005278
SELLAS Life Sciences Group, Inc. (Filer) CIK: 0001390478 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-33958 | Film No.: 201070608
SIC: 2834 Pharmaceutical Preparations